Close Menu

NEW YORK – Aprea Therapeutics said on Wednesday that it will initiate a Phase I trial exploring the activity of APR-548 in TP53-mutant myelodysplastic syndromes (MDS).

APR-548 is a small molecule reactivator of mutant p53 that Boston-headquartered Aprea is developing for oral administration. Half of all tumors harbor mutations in TP53, making it one of the most common genetic aberrations involved in cancer, and cancer patients with TP53 mutations in their tumors often have poor overall survival and tend to develop resistance to available therapies.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Jun
16
Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.